ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.

Prediabetes Market to hit USD 360.6 million by 2032, says Global Market Insights Inc. Selbyville, Delaware, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Prediabetes Market size is estimated to reach USD 360.6 million by the end of 2032. The industry growth is driven by the increasing global...

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).

Cardiometabolic Drugs Market revenue to exceed USD 72 Billion by 2035, says Research Nester New York, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The global Cardiometabolic Drugs Market size is projected to expand at ~ 6% CAGR between 2023 and 2035. The market is expected to garner a revenue of USD...

GLP-1 Receptor Agonist Market to reach USD 55.8 billion by 2032, Says Graphical Research Powered by GMI Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- GLP-1 Receptor Agonist Market size is estimated to amass USD 55.8 billion by 2032. The industry is set to observe notable growth driven...